A multicentred phase III comparative clinical trial of depot-medroxyprogesterone acetate given three-monthly at doses of 100mg or 150mg: 1. Contraceptive efficacy and side effects
Authors:
- S. SaidSSS. Said
- K. OmarKOK. Omar
- Suporn KoetsawangSKSuporn Koetsawang
- Orawan KiriwatOKOrawan Kiriwat
- Yuwadee SrisatayapanYSYuwadee Srisatayapan
- A. KaziAKA. Kazi
- F. AjmalFAF. Ajmal
- H.H. WynterHWH.H. Wynter
- A. Pretnar-DarovecAPA. Pretnar-Darovec
- I.B. BenitezIBI.B. Benitez
- J. de la CruzJCJ. de la Cruz
- R. ApeloRAR. Apelo
- 1 September 1986
- journal article
- research article
- Published by Elsevier in Contraception
- Vol. 34 (3) , 223-235
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Life‐table methods for contraceptive researchStatistics in Medicine, 1986
- Ovarian function following a single administration of depomedroxyprogesterone acetate (DMPA) at different dosesFertility and Sterility, 1984
- Multinational comparative clinical trial of long-acting injectable contraceptives: Norethisterone enanthate given in two dosage regimens and depot-medroxyprogesterone acetate. Final reportContraception, 1983
- Pharmacokinetic study of different doses of Depo ProveraContraception, 1980
- RETURN OF FERTILITY AFTER DISCONTINUATION OF DEPOT MEDROXYPROGESTERONE ACETATE AND INTRA-UTERINE DEVICES IN NORTHERN THAILANDThe Lancet, 1980